Nature Reviews Cancer最新文献

{"title":"Imaging lung lymphatics in action in metastatic cancer","authors":"Simon J. Cleary","doi":"10.1038/s41568-025-00844-5","DOIUrl":"10.1038/s41568-025-00844-5","url":null,"abstract":"In this Tools of the Trade article, Simon Cleary describes the development of a new stabilization window for intravital imaging, which allows the visualization of leukocytes, cancer cells and fluid moving through living lungs.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 9","pages":"653-653"},"PeriodicalIF":66.8,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How team science tackled gender inequalities in Lynch syndrome-associated cancer care","authors":"Emma J. Crosbie","doi":"10.1038/s41568-025-00837-4","DOIUrl":"10.1038/s41568-025-00837-4","url":null,"abstract":"In this World View, Emma J. Crosbie, leader of Team Womb, which was awarded the prestigious 2024 American Association for Cancer Research Team Science Award for work on Lynch syndrome-associated endometrial cancer, argues that cancer discovery and its clinical translation demands a team science approach. Team Womb, led by Emma J. Crosbie at the University of Manchester, was awarded the prestigious 2024 American Association for Cancer Research Team Science Award for work on Lynch syndrome-associated endometrial cancer. In this World View, she argues that cancer discovery and its clinical translation demand a team science approach.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 9","pages":"649-650"},"PeriodicalIF":66.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuro-immune cross-talk in cancer","authors":"Moran Amit, Tuany Eichwald, Anais Roger, Jennifer Anderson, Aeson Chang, Paola D. Vermeer, Karen O. Dixon, Nicole N. Scheff, Sebastien Talbot","doi":"10.1038/s41568-025-00831-w","DOIUrl":"10.1038/s41568-025-00831-w","url":null,"abstract":"The nervous and immune systems have co-evolved to detect and respond to internal and external threats, working together to restore homeostasis after tissue injury or infection. Sharing several receptors and ligands, they engage in direct cross-talk that substantially influences disease development. The emerging field of cancer neuro-immunity focuses on the intricate interactions between the nervous system, immune responses and tumour growth. Additional findings have revealed that nerve fibres infiltrating peripheral tumours can release neuromodulatory factors that shape both immune cell behaviour and tumour progression. Conversely, tumour-infiltrating immune cells can modify the activity of local neurons, including pain-transmitting nociceptive sensory neurons. Beyond sensory fibres, sympathetic signalling can foster immunosuppression by recruiting myeloid-derived suppressor cells and promoting T cell exhaustion. This Review summarizes current evidence on how neuronal signalling regulates peripheral antitumour immune responses within the tumour microenvironment. We describe the complex, reciprocal interactions among neurons, immune cells and malignant cells, highlighting the key parts played by the peripheral nervous system in modulating immunity against cancer. By understanding this neuro-immune axis, novel therapeutic approaches may be uncovered to strengthen antitumour immunity and enhance responses to existing cancer treatments. The nervous and immune systems have co-evolved to respond to threats, including cancer. In this Review, Amit et al. outline the reciprocal interactions among neurons, immune cells and tumour cells that regulate peripheral antitumour immune responses and discuss how these mechanisms could be leveraged to enhance immunotherapy.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 8","pages":"573-589"},"PeriodicalIF":66.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144296053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Energizing leukaemia","authors":"Anna Dart","doi":"10.1038/s41568-025-00842-7","DOIUrl":"10.1038/s41568-025-00842-7","url":null,"abstract":"Sharma et al. discovered that bone marrow osteolineage cells are producers of taurine in the leukaemia niche, which in turn drives leukaemia stem cell survival and self-renewal.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 7","pages":"491-491"},"PeriodicalIF":66.8,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144260482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heard immunity in CAR T cells","authors":"Gabrielle Brewer","doi":"10.1038/s41568-025-00839-2","DOIUrl":"10.1038/s41568-025-00839-2","url":null,"abstract":"The efficacy of chimeric antigen receptor (CAR) T cell therapies in solid tumours is still limited by on-target, off-tumour toxicities. Now, Liu, He, Wang et al. engineered EchoBack-CAR T cells, an ultrasound activated, genetically modified CAR T cell that enables precise spatiotemporal activation.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 7","pages":"490-490"},"PeriodicalIF":66.8,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AACR 2025","authors":"Daniela Senft","doi":"10.1038/s41568-025-00843-6","DOIUrl":"10.1038/s41568-025-00843-6","url":null,"abstract":"The 2025 annual meeting of the American Association for Cancer Research (AACR) was held under the theme ‘Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact’. Here, we summarize some key highlights from the meeting.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 7","pages":"490-490"},"PeriodicalIF":66.8,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144260483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory T cells in the tumour microenvironment","authors":"Charlotte J. Imianowski, Qiang Chen, Creg J. Workman, Dario A. A. Vignali","doi":"10.1038/s41568-025-00832-9","DOIUrl":"10.1038/s41568-025-00832-9","url":null,"abstract":"The powerful suppressive capabilities of regulatory T (Treg) cells and their appreciable contribution to tumour progression make them attractive immunotherapeutic targets. However, their role in systemic immune homeostasis makes it important to find ways to specifically target tumour-infiltrating Treg cells while leaving the wider system unperturbed. It is also unknown whether therapies depleting or disrupting the function of tumour-infiltrating Treg cells will provide the greatest efficacy while limiting immune-related adverse events. In addition, Treg cells share much of their biology with conventional CD4+ T cells, introducing challenges when designing targeted immunotherapies. In this Review, we discuss recent advances in differentiating tumour-infiltrating Treg cells from their systemic and tissue-resident counterparts and understanding how the biology of tumour-infiltrating Treg cells differs from conventional CD4+ T cells. We also discuss how recent technological advances may enable the study of tumour-infiltrating Treg cells in even greater detail, helping to identify new targets for next-generation immunotherapeutic drugs. This Review by Imianowski et al. outlines the various contributions that regulatory T cells, present in the tumour microenvironment, make towards tumour progression and highlight the ways in which they represent attractive next-generation immunotherapeutic targets.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 9","pages":"703-722"},"PeriodicalIF":66.8,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144252007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired resistance in cancer: towards targeted therapeutic strategies","authors":"Alice Soragni, Erik S. Knudsen, Thomas N. O’Connor, Cristina E. Tognon, Jeffrey W. Tyner, Beatrice Gini, Donghwa Kim, Trever G. Bivona, Xingxing Zang, Agnieszka K. Witkiewicz, David W. Goodrich, Dadi Jiang, Seth T. Gammon, Christopher D. Willey, Paul C. Boutros, Vlad C. Sandulache, Abdullah A. Osman, Jeffrey N. Myers, Kamiya Mehla, Pankaj K. Singh, Keith S. Chan, Hongbo Gao, Himangi Marathe, on behalf of National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet)","doi":"10.1038/s41568-025-00824-9","DOIUrl":"10.1038/s41568-025-00824-9","url":null,"abstract":"Development of acquired therapeutic resistance limits the efficacy of cancer treatments and accounts for therapeutic failure in most patients. How resistance arises, varies across cancer types and differs depending on therapeutic modalities is incompletely understood. Novel strategies that address and overcome the various and complex resistance mechanisms necessitate a deep understanding of the underlying dynamics. We are at a crucial time when innovative technologies applied to patient-relevant tumour models have the potential to bridge the gap between fundamental research into mechanisms and timing of acquired resistance and clinical applications that translate these findings into actionable strategies to extend therapy efficacy. Unprecedented spatial and time-resolved high-throughput platforms generate vast amounts of data, from which increasingly complex information can be extracted and analysed through artificial intelligence and machine learning-based approaches. This Roadmap outlines key mechanisms that underlie the acquisition of therapeutic resistance in cancer and explores diverse modelling strategies. Clinically relevant, tractable models of disease and biomarker-driven precision approaches are poised to transform the landscape of acquired therapy resistance in cancer and its clinical management. Here, we propose an integrated strategy that leverages next-generation technologies to dissect the complexities of therapy resistance, shifting the paradigm from reactive management to predictive and proactive prevention. Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss the mechanisms of acquired resistance and the models to better study it. Finally, they promote integration of biomarker-driven strategies and cutting-edge technologies to advance predictive and proactive prevention in cancer therapy.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 8","pages":"613-633"},"PeriodicalIF":66.8,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy","authors":"Dennis X. Beringer, Trudy Straetemans, Susana Minguet, Caterina Riillo, Lydia Lynch, Zsolt Sebestyen, Jürgen Kuball","doi":"10.1038/s41568-025-00830-x","DOIUrl":"10.1038/s41568-025-00830-x","url":null,"abstract":"γδT cell biology in cancer has been studied for decades but remains poorly understood mainly due to species differences in preclinical models and a lack of appropriate analytical tools. This lack of knowledge has hindered the clinical translation of promising therapeutic concepts. In recent years, advanced single-cell analysis techniques and comprehensive protein–protein interaction studies have transformed our understanding of γδT cells and their receptors. This insight has revealed new opportunities and challenges in harnessing γδT cells for therapeutic purposes. In this context, we will discuss the latest findings in γδT cell biology, with a special focus on their role in cancer immune therapies. We will explore strategies to overcome tolerance and shift the balance of γδT cells and their receptors towards antitumour efficacy, which has the potential to successfully translate into various engineering approaches in cancer immunotherapy. In this Review, Beringer and colleagues highlight how future strategies for developing immunotherapies using γδT cells and their receptors will depend on creating intentional imbalances between activating and inhibitory receptors through the genetic engineering of γδT cell-inspired biologics and cellular therapies.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 8","pages":"590-612"},"PeriodicalIF":66.8,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144192850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing the gaps in cancer screening for LGBTQ+ individuals","authors":"Jenna Davison, Mauricio Jin, Emily Leasure, Victor Chedid","doi":"10.1038/s41568-025-00835-6","DOIUrl":"10.1038/s41568-025-00835-6","url":null,"abstract":"Individuals of sexual and gender minorities, particularly transgender and non-binary individuals, face substantial disparities in cancer screening owing to stigma, discrimination, provider misconceptions and systemic barriers. Here, we explore these challenges and call for inclusive healthcare practices and policies to ensure equitable access to cancer screening. Individuals of sexual and gender minorities (SGMs), particularly transgender and nonbinary individuals, face substantial disparities in cancer screening. Here, Davison et al. explore these challenges and call for inclusive healthcare practices and policies to ensure equitable access to cancer screening.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 8","pages":"567-568"},"PeriodicalIF":66.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}